AURKA and cancer: Because of their role in EMT-mediated cancer cell plasticity, drug resistance and ultimately poor clinical outcome, TGF-β and AURKA oncogenic pathways represent attractive druggable targets, and several small molecule inhibitors of TGF-β and AURKA activity are under clinical investigation [38–42].